A New Era of Renal Denervation Trials for Patients With Hypertension? Fatima Jalil, William B. White American Journal of Kidney Diseases Volume 71, Issue 5, Pages 615-618 (May 2018) DOI: 10.1053/j.ajkd.2017.11.009 Copyright © 2017 National Kidney Foundation, Inc. Terms and Conditions
Figure 1 Summary of goals and pathways to address the goals for the development of device therapies in hypertension. ∗BDNF, brain-derived neurotrophic factor. ∗∗Phase 2 study could be performed before phase 3 or nested within the phase 3 trial. Abbreviation: BP, blood pressure. Reproduced from White et al5 with permission of Elsevier. American Journal of Kidney Diseases 2018 71, 615-618DOI: (10.1053/j.ajkd.2017.11.009) Copyright © 2017 National Kidney Foundation, Inc. Terms and Conditions